

1 **Original Article**

2

3 Vera Höllriegl, Astrid Barkleit, Vladimir Spielmann, Wei Bo Li

4

5 **Measurement, model prediction and uncertainty quantification of plasma clearance of cerium citrate**
6 **in humans**

7

8 Vera Höllriegl (✉), Vladimir Spielmann, Wei Bo Li

9 Institute of Radiation Medicine, Helmholtz Zentrum München, German Research Center for
10 Environmental Health, Ingolstädter Landstrasse 1, 85764 Neuherberg, Germany

11 E-mail: vera.hoellriegl@helmholtz-muenchen.de

12 Phone: 0049-(0)89-3187-3219

13 Fax: 0049-(0)89-3187-3846

14

15 Astrid Barkleit

16 Institute of Resource Ecology, Helmholtz-Zentrum Dresden - Rossendorf, Bautzner Landstraße 400,
17 01328 Dresden, Germany

18

19

20

21 **Abstract** Double tracer studies in healthy human volunteers with stable isotopes of cerium citrate were
22 performed with the aim of investigating the gastro-intestinal absorption of cerium (Ce), its plasma
23 clearance and urinary excretion. In the present work, results of the clearance of Ce in blood plasma are
24 shown after simultaneous intravenous and oral administration of a Ce tracer. Inductively coupled
25 plasma mass spectrometry was used to determine the tracer concentrations in plasma. The results show
26 that about 80% of the injected Ce citrate cleared from the plasma within the five minutes post-
27 administration. The data obtained are compared to a revised biokinetic model of cerium, which was
28 initially developed by the International Commission on Radiological Protection (ICRP). The measured
29 plasma clearance of Ce citrate was mostly consistent with that predicted by the ICRP biokinetic model.
30 Furthermore, in an effort to quantify the uncertainty of the model prediction, the laboratory animal
31 data on which the ICRP biokinetic Ce model is based, was analyzed. The measured plasma clearance
32 and its uncertainty was also compared to the plasma clearance uncertainty predicted by the model. It
33 was found that the measured plasma clearance during the first 15 minutes after administration is in a
34 good agreement with the modelled plasma clearance. In general, the measured clearance falls inside
35 the 95% confidence interval predicted by the biokinetic model.

36

37 **Keywords:** Cerium, Biokinetics, Systemic model, Speciation, Internal dosimetry, Uncertainty analysis

38

39

40 Introduction

41 Cerium (Ce), a lanthanide, is the most abundant rare-earth element (REE) found in nature. As Ce is of
42 wide interest for industry, medicine and agriculture, excessive mining to extract Ce (and the other
43 REEs) from mineral ores and their processing leads to a growing environmental pollution and,
44 therefore, to an increasing human exposure possibly involving health effects (Pagano et al. 2015; EPA
45 2012). The production of REE-rich phosphate fertilizers and their application increase the REE
46 concentration in soil, plants, and ground/surface water (Tyler 2004; Li et al. 2013). Hence, the daily
47 intake of cerium by food ingestion (up to 35 μg) is expected to rise steadily (Wappelhorst et al. 2002;
48 Stanek et al. 1997; Linsalata et al. 1986). Besides very low Ce concentrations in human blood of less
49 than 0.008 – 0.07 $\mu\text{g L}^{-1}$ (Höllriegl et al. 2010; Heitland and Köster 2006), much higher values up to 603
50 $\mu\text{g L}^{-1}$ could be found in exposed humans living near mining areas or regions with naturally high
51 background of Ce (Li et al. 2014).

52 Cerium is also of interest for radiation protection, due to its radioactive isotopes ^{141}Ce and ^{144}Ce , which
53 are beta/gamma-emitters with physical half-lives of 33 days and 284 days, respectively. Radionuclides
54 of Ce are produced in $^{235}\text{U}/^{239}\text{Pu}$ nuclear power and processing plants and may be released during
55 nuclear accidents (Zheltonozhsky et al. 2001). These radionuclides may pose serious health risks to
56 workers and members of the public, depending on the amount released into the environment.
57 Incorporation of Ce radionuclides into the human body may occur by inhalation or ingestion, or through
58 absorption by the skin or by wounds. A biokinetic and dosimetric model for the calculation of doses
59 from intakes of radionuclides of lanthanides (including cerium) was developed by the International
60 Commission on Radiological Protection (ICRP) (ICRP 1989, 1993). This model is mainly based on data
61 from studies with animals which had incorporated lanthanides or their chemical analogues (actinides).
62 Unfortunately, for humans there are not much data on the biokinetic behaviour of Ce published. Based
63 on the reviews of Taylor and/or Leggett (Leggett et al. 2014; Taylor and Leggett 2003) improvements of
64 the biokinetic ICRP Ce model will be published soon in the Occupational Intakes of Radionuclides Series
65 (OIR) of the ICRP (in preparation).

66 It is further noted that most of the biokinetic experiments that were performed in the past to provide
67 data for Ce biokinetic modelling used Ce (and/or other lanthanides) in chemical forms without
68 considering any chemical speciation; therefore, the currently available biokinetic models are non-
69 specific. However, as clearly stated by Paquet et al. (2003), “in the case of internal contamination with
70 radionuclides, speciation studies could help to improve both the biokinetic and dosimetric models for
71 radionuclides” (Paquet et al. 2003). Therefore, further biokinetic studies with human volunteers are

72 required to obtain reliable data describing the biokinetics of Ce in humans, ideally considering the
73 chemical speciation of the administered substances.

74 Consequently, a human study on the biokinetics of Ce was initiated including two isotopically enriched
75 stable tracers of Ce with the aim to describe the gastrointestinal absorption of Ce, its distribution
76 throughout the human body and its urinary excretion (Keiser et al. 2011). The isotopes chosen, ^{136}Ce
77 and ^{138}Ce , were simultaneously administered to human volunteers as Ce-III-citrate complexes, one
78 orally and the other intravenously. This double tracer technique was introduced by De Grazia et al.
79 (De Grazia et al. 1965) as an effective method for the determination of the fractional absorption of an
80 ingested substance, and for the determination of the clearance from the plasma and of the urinary
81 excretion rate of an ingested and injected substance. Over the last years, this technique was modified
82 and applied to several elements (Cantone et al. 1993; Cantone et al. 1998; Giussani et al. 2008; Greiter
83 et al. 2011; Roth et al. 1999; Veronese et al. 2001; Höllriegl et al. 2006). The technique can be applied
84 to elements with more than one stable isotope, if the natural isotopic composition of this element is
85 known. For cerium this was the case. The tracer concentrations should be as low as possible, in order
86 not to disturb the normal metabolism of the naturally occurring substance. Therefore, very low
87 concentrations of the tracer substance in plasma or urine samples have to be measured, which is
88 technically challenging. In addition, sources of interferences during the measurement must be avoided
89 or at least be controllable. In the present study, initially thermal ionization mass spectrometry (TIMS)
90 was considered as a suitable measurement technique. Unfortunately, this technique failed to
91 eliminate the known interferences from barium (Ba) at the isotope masses 136 and 138, in spite of
92 intensive sample preparation and purification (Pourmand and Dauphas 2010). As alternative method,
93 inductively coupled plasma sector field mass spectrometry (ICP-SF-MS) was chosen, although the
94 same interferences from Ba could also disturb the ICP-SF-MS measurements. However, to solve this
95 interference problem, the ^{140}Ce concentration of the plasma samples were measured as the relative
96 abundance of ^{140}Ce was also substantial in both applied tracers enriched in ^{136}Ce or ^{138}Ce (Table 1).

97 Recently, results from the same human cohort on the excretion of Ce citrate in urine were presented
98 (Höllriegl et al. 2017). The results showed excretion rates of Ce that were higher as compared to those
99 calculated with the systemic model for cerium proposed by Taylor and Leggett (Leggett et al. 2014).
100 This difference was attributed to the specific chemical form of the cerium administered to the human
101 volunteers, which could not be adequately considered in the biokinetic model. In contrast, the present
102 work shows the plasma clearance of the administered Ce citrate in humans as compared to that
103 predicted by the biokinetic Ce model of Taylor and Leggett.

104 Biokinetic models are essential for calculation of internal radiation dose and associated risk for
105 occupational workers, members of the public and patients exposed to radionuclides; consequently,
106 such models underpin regulatory policy decisions in radiation protection. However, the required model
107 parameters are derived mostly from experimental data obtained from laboratory animals and from
108 analyses of accidental human contamination cases. According to ISO/IEC 17025 (ISO 2005), the
109 uncertainty of the measurement results is necessary to be reported for uncertainty quantification of
110 further derived quantities. The above mentioned parameters are often subject to significant
111 uncertainties, due to the physiological variability of individuals, the uncertainty in the extrapolation of
112 animal data to humans, uncertainties in measurement techniques, the sparsity of and/or inconsistency
113 in the reported data, and the choice of parameter values (NCRP 1996, 1998, 2009; IAEA 1998; Leggett
114 2001; Li et al. 2015). The uncertainty of these model parameters should be provided according to ISO
115 GUM (ISO et al. 1995).

116 **Materials and Methods**

117 **Biokinetic investigations**

118 Recently, a biokinetic study based on the use of two stable isotopes of cerium citrate as tracers was
119 initiated in healthy adult volunteers, to obtain biokinetic data in humans (Keiser et al. 2011). The study
120 was performed according to a protocol approved by the Ethical Committee of the Technical University
121 Munich, Germany. Written consent was obtained from the volunteers before each investigation.

122 Briefly, 100 µg (0.7 µmol) ¹³⁶Ce and 1 µg (0.007 µmol) ¹³⁸Ce tracer as Ce-III-citrate complexes were
123 simultaneously administered orally and intravenously, respectively. The applied Ce-III-citrate
124 complexes were very stable with a formation constant of log beta₂ of about 11.2 (Ohyoshi et al. 1972).
125 Citrate complexes were used because citrate is a common chelating substance and present in the
126 blood plasma as buffering material. Besides, citrate is also present naturally in many geologic fluids
127 and, due to its strong chelating properties, it is used in the decontamination of nuclear facilities
128 (Prakash et al. 2013). The quantity of the administered Ce tracers needed for the study was estimated
129 based on natural intake values of Ce, its concentration in blood or daily excretion, and some
130 toxicological considerations (Linsalata et al. 1986; Wappelhorst et al. 2002; Sabbioni et al. 1982;
131 Minoia et al. 1990; Jakupc et al. 2005; Health Effects Institute 2001). After administration, 10 mL
132 blood samples were taken via an in-dwelling catheter (heparinized) at fixed times post-administration.
133 More specifically, the intended time schedule was 5', 10', 15', 30', 60', 2h, 3h, 4h, 6h, 8h, and 24h;
134 the exact time of blood drawing was recorded and used for further calculations; for example, the

135 blood collection of one specific data set started always 1.5 minutes later than intended. One blood
136 sample (blank) was taken a few minutes before Ce administration, and the first few milliliters of blood
137 were discarded, in order to eliminate any possible contamination of the catheter needle. The blood
138 samples were centrifuged at 3000 rotations per minute (rpm) for 10 minutes and the plasma was
139 collected. All plasma samples were stored frozen until analysis. After thawing, the plasma samples
140 were prepared and analysed using inductively coupled plasma mass spectrometry (ICP-MS).

141 Table 2 presents the characteristics of the ten volunteers (two females, eight males). The plasma
142 volumes of the volunteers were calculated based on their body masses (Moore et al. 1963).

143

144 **Inductively coupled plasma mass spectrometry**

145 For the ICP-MS measurements, the 3.5 mL plasma samples were first transferred to microwave plastic
146 tubes, and 3 mL 65 % HNO₃ and 100 µL H₂O₂ were added. The samples were then treated in a microwave
147 oven for 45 minutes at 60 bar and 240 °C, with a maximum energy of 600 W. After the microwave
148 digestion procedure, the ¹³⁶Ce, ¹³⁸Ce, ¹⁴⁰Ce and ¹⁴²Ce concentrations were measured with a NexION 350X
149 mass spectrometer (Perkin Elmer). Instrument parameters are given in Table 3. Unfortunately, ¹³⁶Ce
150 and ¹³⁸Ce could not be quantified because of known barium interferences at masses 136 and 138
151 (Höllriegl et al. 2017). For further analysis, the measured ¹⁴⁰Ce concentrations were used, because ¹⁴⁰Ce
152 was present in both applied tracers (Table 1). Three measurements were made per sample, and the
153 mean value and the standard deviation were calculated. The limit of detection (LOD) was 0.01 µg L⁻¹
154 and the limit of quantification (LOQ) was 0.05 µg L⁻¹ (Currie 1968). These values were mainly governed
155 by the digestion procedure and the sample dilution necessary for the ICP-MS measurement.

156

157 **Biokinetic modelling**

158 The biokinetic model of cerium proposed by Taylor and Leggett (Taylor and Leggett 2003; Leggett et al.
159 2014) was applied to simulate the plasma clearance of Ce and to compare the model data with the
160 experimental results obtained in the present study. The structure of the systemic model for cerium used
161 here is shown in Fig. 1. After its injection, cerium is cleared from the circulation with a biological half-
162 life of approximately 30 minutes. Subsequently, Ce is homogeneously distributed in organs and tissues,
163 mainly in the liver (50%) and bone (30%). About 2% of injected Ce from plasma is excreted into urine
164 within the biological half-life of 30 minutes. The plasma clearance is influenced by the rapid

165 equilibration of Ce with the extra-cellular fluid (ECF) which is part of the plasma; in the biokinetic model
166 the ECF is modelled by the soft tissue compartment ST0 (Fig. 1). Recycling of Ce between the tissue
167 compartments and blood plasma is included in the model allowing for different biological half-lives. The
168 model parameters (transfer coefficients) were taken from Leggett et al. (2014) and implemented in the
169 SAAM II ver2.3 computer program (Barrett et al. 1998). For the simulations, 1 µg Ce for the injection
170 and 100 µg Ce for the ingestion were used, as well as two different plasma volumes of 3.6 L (for the
171 male volunteers) and of 2.4 L (for the females) (see Table 2). Although the reference plasma volumes
172 proposed by the ICRP are 3.0 L for males and 2.4 L for females (ICRP 1989), the mean plasma volumes
173 of the participating male volunteers was 3.6 L and higher than the ICRP reference value. Consequently,
174 this value was taken for the simulations instead of 3.0 L.

175

176 **Uncertainty analysis**

177 According to the ISO Guide (ISO 1995), the measurement uncertainty is the parameter associated with
178 the result of a measurement that characterizes the dispersion of the values that could reasonably be
179 attributed to the measurand. Uncertainty analysis requires computation of the total uncertainty
180 induced in the output of a simulation. This in turn requires quantification of the input and model
181 uncertainties, and the attributes of the relative importance of the input uncertainties in terms of their
182 contributions to the output (Morgan and Henrion 1990). The method can be applied both to measured
183 data and model parameters. To quantify the measurement uncertainties, the standard deviation of
184 plasma clearance as deduced from the ICP-MS measurements was used in the present study. The
185 uncertainty of parameters of the ICRP Ce biokinetic model was analyzed by evaluating the animal data
186 on which the ICRP biokinetic Ce model used in the present study was based. In addition, according to
187 the results of the parameter uncertainty analysis, the model parameters were sampled and imported
188 as input to the computer code BIODOS. This code was developed for internal dosimetry uncertainty
189 analysis (Li et al. 2011; Li et al. 2015). The uncertainty of the model prediction was calculated from the
190 computer-simulated outputs and was compared to the uncertainty of the measured human data (partly
191 mean values with standard deviation). The biokinetic parameters (transfer coefficients) k_{ij} were
192 calculated by Eq. 1:

$$k_{ij} = \frac{\ln 2}{T_j} a_{ij} \quad (1)$$

193 where T_j is the removal half-life (d) from the compartment j ; and a_{ij} is a fraction of activity in
194 compartment j transferred to compartment i .

195 Numerical values of the variables k_{ij} , T_j , a_{ij} can be found in the literature (Taylor and Leggett 2003,
196 1998; Leggett et al. 2014; ICRP 1989). It was assumed that the values of these variables follow a normal
197 distribution. For those biokinetic parameters for which the available experimental data did not allow
198 estimation of any uncertainty, a coefficient of variation (cv) of 20% was assumed here. The cv is
199 considered to be one of the most widely used statistical measures of the relative dispersion. Values for
200 the cv of 16%, 17% and 31% were obtained from cited references by evaluating the animal data on
201 which the ICRP biokinetic Ce model was based (ICRP 1989; Taylor and Leggett 1998, 2003; Leggett et al.
202 2014). For the confidence interval of 95%, a coefficient of variation of 20% corresponds to a coverage
203 probability of more than 99.2% (Sappakitkamjorn and Niwitpong 2013). In the present work, the mean
204 values of these transfer coefficients k_{ij} were set to be the values reported by Leggett et al. (2014). The
205 standard deviation σ can be calculated for all statistical values based on Eq. 2:

$$cv = \frac{\sigma}{\mu} \quad (2)$$

206 Where μ is the mean value.

207 The standard deviation for any parameter was calculated using standard deviations for the variables
208 T_i , a_{ij} and applying the propagation of uncertainty. Based on a normal distribution and a confidence
209 interval of 95%, the minimum and maximum values (97.5th and 2.5th percentiles of the normal
210 distribution) of the model parameters k , which are used for the Latin hypercube sampling (LHS) (Iman
211 and Shortencarier 1984) technique, were calculated as follows (Eqs. 3 and 4):

$$Minimum = \mu - 1.96\sigma \quad (3)$$

$$Maximum = \mu + 1.96\sigma \quad (4)$$

212 The model parameters and the uncertainties are presented in Table 4.

213

214 **Results and Discussion**

215 Measurements of the normal cerium concentrations in blood plasma resulted in very low values (<0.008
216 – 0.07 $\mu\text{g L}^{-1}$) (Höllriegl et al. 2010; Heitland and Köster 2006). In the present study, the cerium

217 concentrations in the plasma (before administration of the Ce tracers) were less than $0.05 \mu\text{g L}^{-1}$, which
218 means that most of the measured values were below the LOQ.

219 Table 5 presents the results of the plasma concentration of Ce at fixed time points post-administration
220 for all ten human volunteers. At five minutes after injection, only half of the samples showed
221 measurable Ce concentrations, while the other samples showed values below the LOQ of $0.05 \mu\text{g L}^{-1}$;
222 30 minutes after administration, all Ce concentrations were below the LOQ. It can be assumed that
223 the measurable Ce concentrations were derived from the intravenous injection of ^{138}Ce , and not from
224 the orally administered ^{136}Ce , as a single oral Ce citrate administration (of $100 \mu\text{g}$) would not result in
225 a significant increase of the Ce concentration in plasma, due to the low gastrointestinal absorption
226 factor for Ce of 5×10^{-4} (Leggett et al. 2014). It is noted that thermal ionisation mass spectrometry
227 (TIMS) would allow measurement of a very low mass of Ce tracers in human plasma, i.e. about 1 ng
228 per sample, and thus, detection of a small increase in Ce concentration after ingestion of $100 \mu\text{g}$ of Ce
229 citrate. As mentioned above, although the plasma samples were intensively processed (Pourmand and
230 Dauphas 2010), the sources of interferences from barium in these samples could not be removed in
231 the present study. The fact that Ce concentrations were too low to be detected in many of the
232 investigated samples is certainly a drawback of the present study. Nevertheless, it is obvious that the
233 plasma clearance of Ce citrate of the volunteers was very fast. On average, within the first five minutes
234 more than 80% of Ce disappeared from the plasma. To better follow the rapid decrease of Ce in the
235 plasma during the early phase after injection, blood collection starting about one minute after tracer
236 injection would have been preferable.

237 In fact, animal studies on the blood clearance of Ce showed indeed an extremely fast clearance during
238 the first minutes after intravenous injection. For example, Aeberhardt et al. found that 50% of Ce
239 (administered as colloidal Ce) disappeared from the blood of rats already one minute after tracer
240 injection; and after five minutes, about 91% of Ce was cleared from the blood (Aeberhardt et al. 1962).
241 Similarly, Durbin et al. reported an almost complete disappearance of Ce during the first five minutes
242 after injection of Ce citrate in rats (Durbin et al. 1955). An initial removal half-life from blood plasma of
243 one minute was discussed, which was assumed to represent the equilibration time of the administered
244 Ce in plasma with the extracellular fluid (ECF) and highly vascularized tissues. A second but longer half-
245 life of 17 minutes from 5-60 minutes post-administration was assumed to represent the uptake of Ce
246 in organs and tissues, the urinary excretion, and the re-entry of Ce into the plasma from other tissues.
247 Obviously, these animal studies show fast clearance rates similar to those observed in the present
248 human study.

249 Figure 2 presents the plasma clearance measured in the present study and, for comparison, the
250 clearance predicted by the biokinetic model of Leggett (Leggett et al. 2014). Two model curves are
251 shown, one applying a plasma volume of 2.4 L, the other a plasma volume of 3.6 L. The model curves at
252 5-10 minutes after injection are largely consistent with the measured data that are above LOQ. It is
253 noted that the only value above the model curves was obtained from a female volunteer. It is also noted
254 that the results for those volunteers for which all results were below LOQ (one female, four males) are
255 not shown in Fig. 2. The biokinetic model curves suggest a slow plasma clearance of Ce between 5 and
256 120 minutes post-administration reaching a plasma level of 5% L⁻¹ after about 84 minutes. In contrast,
257 all experimental values except one reached the LOQ (which corresponded to 5% L⁻¹) much earlier (after
258 about 15 minutes). Although the experimental data obtained in the present study are limited, they
259 suggest a more rapid Ce removal from plasma than the model of Taylor and Leggett implies, which
260 assumed a biological removal half-life from blood of 30 minutes (Taylor and Leggett 2003). Because of
261 the many data, which were below LOQ (Table 5), a corresponding removal rate from plasma, was
262 difficult to calculate, although it will be certainly less than 30 minutes. A half-life of around 10 minutes
263 may be estimated visually from the plotted data. This fast plasma clearance after intravenous injection
264 of Ce citrate may be due to the very stable Ce citrate complex, which shows a more rapid transfer of Ce
265 from the plasma to other compartments of the human body or to a higher urinary excretion than those
266 of a lower complexed or ionic Ce salt. This was already addressed by Höllriegl et al. (Höllriegl et al. 2017).
267 The initial chemical speciation of the administered Ce citrate complex can explain the difference
268 between the clearance observed in the present study and that predicted by the biokinetic model of
269 Taylor and Leggett, which is a systemic model without any consideration of chemical speciation (Taylor
270 and Leggett 1998, 2003).

271 For many years, speciation studies using complexes of REEs (including Ce but also other elements like
272 the actinides) with citrate or with other stable chelating agents like DTPA or EDTA, have been
273 performed, and their results compared particularly with the behaviour of the corresponding inorganic
274 salts (chlorides, nitrates, carbonates) of these elements (Spencer 1963; Aeberhardt et al. 1962; Rosoff
275 et al. 1963; Turner and Taylor 1968; Durbin et al. 1955). It was observed that after intravenous injection,
276 the plasma level of elements in the form of stable chelate complexes decreased at a higher rate than
277 those of elements present in their ionic forms. Depending on the chemical form and stability of the
278 complexes, their distribution in organs or tissues (e.g. liver, bone) as well as their urinary excretion was
279 different (Zhang and Chai 2004; Rosoff et al. 1963). A recent human study demonstrated the influence
280 of the chemical form of ruthenium (Ru) on its kinetics in plasma. It was found that Ru citrate complexes

281 were very rapidly cleared from the plasma with a characteristic half-life of about 17 minutes, while
282 inorganic Ru remained longer in the systemic circulation (Veronese et al. 2004).

283 In the present study, the uncertainty in the predicted plasma clearance of Ce was calculated based on
284 the uncertainties of the biokinetic model parameters (see Table 4), and compared to the measured
285 human Ce clearance and its uncertainty (Fig. 2). Except for one value, the measured mean values are,
286 especially during the early period at 5-10 minutes after tracer injection, within the 95% confidence
287 interval provided by the biokinetic model. It is emphasised, however, that the data below the LOQ are
288 not consistent with the model prediction, because the biokinetic model was assumed to follow a linear
289 and first order kinetics resulting in a slow and smooth decline of plasma clearance. Therefore, the LOQ
290 data cannot reliably be used to validate the model predictions and uncertainties. This calls for further
291 biokinetic measurements with improved experimental techniques. Within the involved uncertainties,
292 however, this study found reasonable agreement between predicted and measured plasma clearance
293 of Ce in humans. This demonstrates that the biokinetic model of Ce can be applied to predict the fast
294 component of plasma clearance after injection. Finally, the influence of the chemical speciation of
295 administered Ce on its biokinetic behaviour in the body is important, and this aspect should be included
296 in biokinetic modelling.

297

298 **Conclusion**

299 The present human Ce study provided new results on the biokinetic behaviour of cerium citrate in
300 blood plasma. After intravenous injection, plasma clearance was very fast within the first few minutes
301 after administration. Given the involved uncertainties, data measured in the present study suggested
302 a faster plasma clearance of Ce than predicted by the biokinetic model of Ce developed by Taylor and
303 Leggett (Taylor and Leggett 1998). The present study suggested an influence of the chemical form of
304 the administered cerium on its plasma clearance rate. Consequently, the importance of the chemical
305 speciation should also be taken into account for biokinetic and dosimetric modelling. Furthermore,
306 additional biokinetic measurements of Ce in blood and various organs and tissues, and urinary
307 excretion of Ce, in particular at times later than those chosen in the present study, are called for. This
308 would need use of advanced technologies offering the possibility to measure lower concentrations
309 than those that could be measured in the present study. This, together with better Ce intake
310 information, would allow further validation and improvement of the current systemic biokinetic
311 model of Ce.

312

313 **Acknowledgements:** We gratefully thank Mrs. Sabrina Beutner for the ICPMS measurements. This
314 work was supported by the German Federal Ministry of Education and Research (BMBF) with contract
315 number 02NUK030A. We thank the reviewers and journal editor for valuable comments and linguistic
316 revisions.

317 **Ethical approval:** All procedures performed in studies involving human participants were in
318 accordance with the ethical standards of the institutional and/or national research committee and
319 with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

320 **Informed consent:** Informed consent was obtained from all individual participants included in the
321 study.

322 **Conflict of interest:** The authors declare that they have no conflict of interest.

323 **References**

- 324 Aeberhardt A, Nizza P, Remy J, Boilleau Y (1962) Etude comparee du métabolisme du cérium 144 en
325 fonction de son état physico-chimique chez le rat. *Int J Radiat Biol* 5 (3):217–246
- 326 Barrett PHR, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, Foster DM (1998) SAAM II:
327 simulation, analysis, and modeling software for tracer and pharmacokinetic studies.
328 *Metabolism* 47:484-492
- 329 Cantone MC, de Bartolo D, Gambarini G, Giussani A, Molho N, Pirola L, Hansen C, Werner E, Roth P
330 (1993) Intestinal absorption of tellurium studied with stable tracers. *J Radioanal Nucl Chem*
331 170 (2):433-442
- 332 Cantone MC, De Bartolo D, Giussani A, Roth P, Werner E (1998) The stable isotope approach to
333 elemental biokinetics. *Radiat Phys Chem* 51:589
- 334 Currie LA (1968) Limits for qualitative detection and quantitative determination. *Anal Chem* 40:586-
335 593
- 336 De Grazia JA, Ivanovic P, Fellows H, Rich C (1965) A double-isotope method for measurement of
337 intestinal absorption of calcium in man. *J Lab Clin Med* 66 (5):822-829
- 338 Durbin PW, Asling GW, Johnston ME, Hamilton JG, Williams MH (1955) The Metabolism of the
339 Lanthanons in the Rat II. Time Studies of the Tissue Deposition of Intravenously
340 Administered Radioisotopes. Report Number: UCRL-3191. Lawrence Radiation Laboratory,
341 Berkeley, California
- 342 EPA (2012) Rare Earth Elements: A Review of Production, Processing, Recycling, and Associated
343 Environmental Issues. US Environmental Protection Agency, Washington, DC
- 344 Giussani A, Cantone MC, Gerstmann U, Greiter M, Hertenberger R, Höllriegl V, Leopold K, Veronese I,
345 Oeh U (2008) Biokinetics of ruthenium isotopes in humans and its dependence on chemical
346 speciation. Paper presented at the 12th International Congress of the International
347 Radiation Protection Association, Buenos Aires, Argentina,
- 348 Greiter MB, Giussani A, Höllriegl V, Li WB, Oeh U (2011) Human biokinetic data and a new
349 compartmental model of zirconium -- A tracer study with enriched stable isotopes. *Sci Total*
350 *Environ* 409:3701-3710
- 351 Health Effects Institute (2001) Evaluation of human health risk from cerium added to diesel fuel.
352 Health Effects Institute, Communication 9, Boston MA, USA
- 353 Heitland P, Köster H (2006) Biomonitoring of 37 trace elements in blood samples from inhabitants of
354 northern Germany by ICP-MS. *J Trace Elem Med Biol* 20:253-262
- 355 Höllriegl V, Gonzalez-Estecha M, Trasobares EM, Giussani A, Oeh U, Herraiz MA, Michalke B (2010)
356 Measurement of cerium in human breast milk and blood samples. *J Trace Elem Med Biol* 24
357 (3):193-199
- 358 Höllriegl V, Li WB, Michalke B (2017) Biokinetic measurements and modelling of urinary excretion of
359 cerium citrate in humans. *Radiat Environ Biophys* 56 (1):1-8
- 360 Höllriegl V, Li WB, Oeh U (2006) Human biokinetics of strontium. Part II: Final data evaluation of
361 intestinal absorption and urinary excretion of strontium in human subjects after stable
362 tracer administration. *Radiat Environ Biophys* 45:179-185
- 363 IAEA (1998) Evaluation the reliability of predictions made using environmental transfer models.
364 International Atomic Energy Agency, Vienna, Austria
- 365 ICRP (1989) Age-dependent doses to members of the public from intake of radionuclides: Part 1:
366 Ingestion dose coefficients. ICRP Publication 56. Pergamon Press, Oxford, UK
- 367 ICRP (1993) Age-dependent doses to members of the public from intake of radionuclides: Part 2:
368 Ingestion dose coefficients. ICRP Publication 67. Pergamon Press, Oxford, UK
- 369 ICRP (2006) Human alimentary tract model for radiological protection. ICRP Publication 100. Elsevier,
370 Oxford, UK

371 Iman RL, Shortencarier MJ (1984) A FORTRAN 77 program and user's guide for the generation of
 372 Latin hypercube and random samples for use with computer models. NUREGKR-3624
 373 (SAND83-2365) Sandia National Laboratories, Albuquerque
 374 ISO (2005) General requirements for the competence of testing and calibration laboratories., vol
 375 ISO/IEC 17025:2005. International Organization for Standardization, Geneva
 376 ISO, BIPM, IEC, IFCC, IUPAC, IUPAP, OIML (1995) Guide to the expression of uncertainty in
 377 measurement (GUM). 1st edn. International Organization for Standardization, Geneva
 378 Jakupec MA, Unfried P, Keppler BK (2005) Pharmacological properties of cerium compounds. Rev
 379 Physiol Biochem Pharmacol 153:101-111
 380 Keiser T, Höllriegl V, Giussani A, Oeh U (2011) Measuring technique for thermal ionisation mass
 381 spectrometry of human tracer kinetic study with stable cerium isotopes. Isotopes Environ
 382 Health Stud 47 (2):238-252
 383 Leggett RW (2001) Reliability of the ICRP's dose coefficients for members of the public. 1. Sources of
 384 uncertainty in the biokinetic models. Radiat Prot Dosim 95:199-213
 385 Leggett RW, Ansoborlo E, Bailey M, Gregoratto D, Paquet F, Taylor DM (2014) Biokinetic data and
 386 models for occupational intake of lanthanoids. Int J Radiat Biol 90:996-1010
 387 Li WB, Greiter M, Oeh U, Hoeschen C (2011) Reliability of a new biokinetic model of zirconium in
 388 internal dosimetry. Part I. Parameter uncertainty analysis. Health Phys 101 (6):660-676
 389 Li WB, Klein W, Blanchardon E, Puncher M, Leggett RW, Oeh U, Breustedt B, Noßke D, Lopez MA
 390 (2015) Parameter uncertainty analysis of a biokinetic model of caesium. Radiat Prot Dosim
 391 163 (1):37-57
 392 Li XF, Chen ZB, Chen ZQ (2014) Distribution and fractionation of rare earth elements in soil-water
 393 system and human blood and hair from a mining area in south-west Fujian Province, China.
 394 Environ Earth Sci 72:3599-3608
 395 Li XF, Chen ZB, Chen ZQ, Zhang YH (2013) A human health risk assessment of rare earth elements in
 396 soil and vegetables from a mining in Fujian Province, Southeast China. Chemosphere 93:1240-
 397 1246
 398 Linsalata P, Eisenbud M, Penna Franca F (1986) Ingestion estimates of Th and the light rare earth
 399 elements based on measurements on human feces. Health Phys 50 (1):163-167
 400 Minoia C, Sabbioni E, Apostoli P, Pietra R, Pozzoli L, Gallorini M, Nicolau G, Alessio L, Capodaglio E
 401 (1990) Trace element reference values in tissues from inhabitants of the European
 402 Community. I. A study of 46 elements in urine, blood and serum of italian subjects. Sci Total
 403 Environ 95:89-105
 404 Moore FD, Olesen KH, McMurrey JD, Parker HV, Ball NR, Boyden CM (1963) The body cell mass and
 405 its supporting environment: Body composition in health and in disease. W.B. Saunders
 406 Company, Philadelphia
 407 Morgan M, Henrion M (1990) Uncertainty. A guide to dealing with uncertainty in quantitative risk
 408 and policy analysis. Cambridge University Press, New York
 409 NCRP (1996) A guide for uncertainty analysis in dose and risk assessments related to environmental
 410 contamination. National Council on Radiation Protection & Measurements, Bethesda, MD
 411 NCRP (1998) Evaluating the reliability of biokinetic and dosimetric models and parameters used to
 412 assess individual doses for risk assessment purposes. National Council on Radiation
 413 Protection & Measurements, Bethesda, MD
 414 NCRP (2009) Uncertainty in internal radiation dose assessment. National Council on Radiation
 415 Protection & Measurement, Bethesda, MD
 416 Ohyoshi A, Ohyoshi E, Ono H, Yamakawa S (1972) A study of citrate complexes of several
 417 lanthanides. J Inorganic Nucl Chem 34:1955-1960
 418 Pagano G, Guida M, Tommasi F, Oral R (2015) Health effects and toxicity mechanisms of rare earth
 419 elements-Knowledge gaps and research prospects. Ecotoxicol Environ Saf 115:40-48

420 Paquet F, Frelont S, Cote G, Madic C (2003) The Contribution of Chemical Speciation to Internal
421 Dosimetry. *Radiat Prot Dosim* 105 (1-4):179-184

422 Pourmand A, Dauphas N (2010) Distribution coefficients of 60 elements on TODGA resin: Application
423 to Ca, Lu, Hf, U and Th isotope geochemistry. *Talanta* 81 (3):741-753

424 Prakash D, Gabani P, Chandel AK, Ronen Z, Singh OV (2013) Bioremediation: a genuine technology to
425 remediate radionuclides from the environment. *Microbial Biotechnology* 6 (4):349-360

426 Rosoff B, Siegel E, Williams GL, Spencer H (1963) Distribution and Excretion of Radioactive Rare-
427 Earth Compounds in Mice. *Int J Appl Radiat Isot* 14:129-135

428 Roth P, Heinrichs U, Giussani A, Zilker T, Felgenhauer N, Greim H (1999) Internal biokinetic behaviour
429 of molybdenum in humans studied with stable isotopes as tracers. *Isotopes Environ Health*
430 *Stud* 33:323-329

431 Sabbioni E, Pietra R, Gaglione P (1982) Long-term occupational risk of rare-earth pneumoconiosis. A
432 case report as investigated by neuron activation analysis. *Sci Tot Environ* 26:19-32

433 Sappakitkamjorn J, Niwitpong S (2013) Confidence Intervals for the Coefficients of Variation with
434 Bounded Parameters. *International Journal of Mathematical, Computational, Physical,*
435 *Electrical, and Computer Engineering* 7 (9):1416-1421

436 Spencer H Metabolism and removal of some radioisotopes in man. In: 65 IP (ed) In: *Diagnosis and*
437 *Treatment of Radioactive Poisoning. Proceedings of a scientific meeting held at Vienna (A),*
438 *15-18 October 1962, jointly organized by WHO and IAEA., 1963. WHO and IAEA,*

439 Stanek EJ, Calabrese EJ, Barnes R, Pekow P (1997) Soil Ingestion in Adults-Results of a Second Pilot
440 Study. *Ecotoxicol Environ Saf* 36:249-257

441 Taylor DM, Leggett RW (1998) A generic biokinetic model for the lanthanide elements. *Radiat Prot*
442 *Dosim* 79:351-354

443 Taylor DM, Leggett RW (2003) A generic biokinetic model for predicting the behaviour of the
444 lanthanide elements in the human body. *Radiat Prot Dosim* 105:193-198

445 Turner GA, Taylor DM (1968) The Transport of Plutonium, Americium and Curium in the Blood of
446 Rats. *Physics Medicine Biology* 13 (4):535-546

447 Tyler G (2004) Rare earth elements in soil and plant systems-A review. *Plant and Soil* 267:191-206

448 Veronese I, Giussani A, Cantone MC, Birattari C, Bonardi M, Groppi F, Höllriegel V, Roth P, Werner E
449 (2004) Influence of the chemical form on the plasma clearance of ruthenium in humans.
450 *Appl Radiat Isot* 60:7-13

451 Veronese I, Giussani A, Cantone MC, de Bartolo D, Roth P, Werner E (2001) Kinetics of systemic
452 ruthenium in human blood using a stable tracer. *J Radiol Prot* 21:31-38

453 Wappelhorst O, Kuehn I, Heidenreich H, Markert B (2002) Transfer of selected elements from food
454 into human milk. *Nutrition* 18 (4):316-322

455 Zhang ZY, Chai ZF (2004) Isotopic tracer studies of chemical behavior of rare earth elements in
456 environmental and biological sciences. *Radiochimica Acta* 92:355-358

457 Zheltonozhsky V, Mück K, Bondarkov M (2001) Classification of hot particles from the Chernobyl
458 accident and nuclear weapons detonations by non-destructive methods. *J Environ Radioact*
459 *57:151-166*

460

461

462 **Table 1** Isotopic composition of the administered cerium tracers as compared to that of natural
 463 cerium and barium

	Relative isotope abundances (atom %)			
	136	138	140	142
natural cerium	0.185	0.25	88.45	11.11
oral ¹³⁶ Ce tracer	30.6	0.7	64.2	4.5
intravenous ¹³⁸ Ce tracer	0.04	41.6	55.81	2.55
natural barium	7.85	71.69		

464

465

466 **Table 2** Data of human volunteers who participated in the present study. M – male; F – female.

Volunteer ID	Sex (F/M)	Age (y)	Mass (kg)	Plasma volume (L)
Ce7	M	31	115	4.55
Ce8	M	54	70	3.13
Ce9	F	48	66	2.56
Ce10	M	22	130	5.02
Ce11	M	30	84	3.57
Ce12	M	28	75	3.29
Ce13	M	30	82	3.51
Ce14	M	27	87	3.66

Ce15	F	62	75	2.79
Ce17	M	44	82	3.51

467

468

469 **Table 3** Instrument parameters used for the inductively coupled plasma mass spectrometry (ICP-MS)
 470 measurements

471

Instrument	NexION 350X, Perkin Elmer
RF power	1300 W
Plasma gas	15 L Ar/min
Nebulizer gas	0.93 – 0.98 L Ar/min
Isotope	¹⁴⁰ Ce
Internal standard	¹⁰³ Rh, at 5 µg/L
Dwell time	50 ms
Replicates	3
Measurement time	2 min
Sample flow rate	250 µL/min
Calibration	
3-point calibration	1 ppt, 5 ppt, 10 ppt
4-point calibration	0.5 ppb, 1 ppb, 2 ppb, 5 ppb

472

473

474

475

476 **Table 4** Uncertainty of the biokinetic parameters of Ce; Mean values represent k-values (k1-k28)
 477 reported by Leggett et al. (2014), and k-values (k29-k34) by ICRP 100 (ICRP 2006) ; Values of q2.5 and
 478 q97.5 are the 2.5th and 97.5th percentiles of the normal distribution, respectively; *cv* = coefficient of
 479 variation; SD – standard deviation

Transfer coefficients k (d ⁻¹) ^a						
	Distribution	q2.5	Mean	q97.5	<i>cv</i> (%)	SD
k1	Normal	8.502 x 10 ⁻¹	11.65	22.44	30	3.490
k2	Normal	5.216 x 10 ⁻¹	9.981	19.48	31	3.070
k3	Normal	1.353 x 10 ⁻¹	1.853	3.570	30	5.560 x 10 ⁻¹
k4	Normal	3.400 x 10 ⁻²	4.658 x 10 ⁻¹	8.976 x 10 ⁻¹	30	1.400 x 10 ⁻¹
k5	Normal	2.551 x 10 ⁻¹	3.494	6.732	30	1.050
k6	Normal	2.551 x 10 ⁻¹	3.494	6.732	30	1.050
k7	Normal	2.551 x 10 ⁻²	3.494 x 10 ⁻¹	6.732 x 10 ⁻¹	30	1.050 x 10 ⁻¹
k8	Normal	1.020 x 10 ⁻¹	1.170 x 10 ⁻¹	2.693	30	4.190 x 10 ⁻¹
k9	Normal	8.502 x 10 ⁻³	1.397	2.244 x 10 ⁻¹	30	3.490 x 10 ⁻²
k10	Normal	5.930 x 10 ⁻⁴	8.150 x 10 ⁻³	1.571 x 10 ⁻²	30	2.450 x 10 ⁻³
k11	Normal	3.401 x 10 ⁻²	4.658 x 10 ⁻¹	8.976 x 10 ⁻¹	30	1.400 x 10 ⁻¹
k12	Normal	3.620 x 10 ⁻⁴	9.490 x 10 ⁻⁴	1.536 x 10 ⁻³	20	1.900 x 10 ⁻⁴
k13	Normal	7.140 x 10 ⁻⁴	2.310 x 10 ⁻³	3.906 x 10 ⁻³	23	5.170 x 10 ⁻⁴
k14	Normal	7.923 x 10 ⁻³	2.079 x 10 ⁻²	3.367 x 10 ⁻²	20	4.170 x 10 ⁻³
k15	Normal	5.296 x 10 ⁻¹	1.386	2.243	20	2.770 x 10 ⁻¹
k16	Normal	7.250 x 10 ⁻⁴	1.899 x 10 ⁻³	3.072 x 10 ⁻³	20	3.800 x 10 ⁻⁴
k17	Normal	4.800 x 10 ⁻⁵	1.280 x 10 ⁻⁴	2.040 x 10 ⁻⁴	20	2.530 x 10 ⁻⁵
k18	Normal	2.901 x 10 ⁻³	7.596 x 10 ⁻³	1.229 x 10 ⁻²	20	1.520 x 10 ⁻³
k19	Normal	3.100 x 10 ⁻⁵	8.200 x 10 ⁻⁵	1.320 x 10 ⁻⁴	20	1.640 x 10 ⁻⁵
k20	Normal	1.500 x 10 ⁻⁵	4.100 x 10 ⁻⁵	6.600 x 10 ⁻⁵	20	8.220 x 10 ⁻⁶
k21	Normal	3.100 x 10 ⁻⁵	8.200 x 10 ⁻⁵	1.320 x 10 ⁻⁴	20	1.640 x 10 ⁻⁵
k22	Normal	2.901 x 10 ⁻³	7.596 x 10 ⁻³	1.229 x 10 ⁻²	20	1.520 x 10 ⁻³
k23	Normal	1.880 x 10 ⁻⁴	4.930 x 10 ⁻⁴	7.970 x 10 ⁻⁴	20	9.860 x 10 ⁻⁵
k24	Normal	9.400 x 10 ⁻⁵	2.470 x 10 ⁻⁴	3.990 x 10 ⁻⁴	20	4.940 x 10 ⁻⁵
k25	Normal	1.880 x 10 ⁻⁴	4.930 x 10 ⁻⁴	7.970 x 10 ⁻⁴	20	9.860 x 10 ⁻⁵
k26	Normal	3.783 x 10 ⁻²	9.900 x 10 ⁻²	1.602 x 10 ⁻¹	20	1.980 x 10 ⁻²
k27	Normal	5.290 x 10 ⁻⁴	1.386 x 10 ⁻³	2.243 x 10 ⁻³	20	2.770 x 10 ⁻⁴
k28	Normal	1.450 x 10 ⁻⁴	3.790 x 10 ⁻⁴	6.140 x 10 ⁻⁴	20	7.600 x 10 ⁻⁵
k29	Normal	4.584	12.00	19.42	20	2.400
k30	Normal	7.052 x 10 ⁻¹	1.750 ^b	2.204	17	2.430 x 10 ⁻¹
k31	Normal	8.273 x 10 ⁻¹	1.750 ^b	2.427	16	2.590 x 10 ⁻¹
k32	Normal	8.273 x 10 ⁻¹	1.750 ^b	2.427	16	2.590 x 10 ⁻¹
k33	Normal	1.926	6.000	6.350	17	7.160 x 10 ⁻¹
K34	Normal	1.236 x 10 ⁻³	3.000 x 10 ⁻³	4.764 x 10 ⁻³	30	9.000 x 10 ⁻⁴

480 ^a Numbering of transfer coefficients (k) see Fig. 1; ^b mean value of 2 (for adult male) and 1.5 (for

481 adult female)

482


483 **Table 5** Cerium concentration of intravenous tracer measured in plasma of ten human volunteers;
 484 SD – standard deviation

Ce concentration in plasma				
$\mu\text{g L}^{-1} (\pm \text{SD})$				
Post-administration time	5 min	10 min	15 min	30 min – 1,440 min
Volunteer ID				
Ce7	<0.05	<0.05	<0.05	<0.05
Ce8	<0.05	<0.05	<0.05	<0.05
Ce9	0.435 (0.199)	0.220 (0.083)	0.207 (0.065)	<0.05
Ce10*	0.336 (0.036)	<0.05	<0.05	<0.05
Ce11	-	0.318 (0.059)	<0.05	<0.05
Ce12	<0.05	<0.05	<0.05	<0.05
Ce13	0.262 (0.122)	<0.05	<0.05	<0.05
Ce14	0.342 (0.120)	0.319 (0.114)	<0.05	<0.05
Ce15	<0.05	<0.05	<0.05	<0.05
Ce17	<0.05	<0.05	<0.05	<0.05

485 *Post-administration time: always 1.5 min later than intended

486


487



488

489 **Fig. 1** Schematic presentation of the systemic model of cerium used in the present study (Leggett et
490 al. 2014). The k_i -values represent the transfer coefficients (d^{-1}) between the different compartments
491 of the model; ST = soft tissue

492



493

494 **Fig. 2** Plasma clearance of cerium after intravenous injection of 1 μg (0.007 μmol) Ce-III-citrate. Tracer
 495 concentrations are given as percent of administered tracer per liter plasma. Different symbols
 496 correspond to data from five human volunteers (one female, four males), who showed measurable
 497 values above limit of quantification (LOQ): Black circle – Ce09; red triangle down – Ce10; green square
 498 – Ce11; yellow diamond – Ce13; blue triangle up – Ce14. Each data point represents the mean of three
 499 measurements; error bars denote the corresponding standard deviation. Horizontal dotted line – LOQ
 500 for Ce at 5.0% L^{-1} . Dashed-dotted lines – biokinetic model curves applying plasma volumes of 2.4 L (for
 501 females, upper curve) and 3.6 L (for males, lower curve); the curves represent Ce concentrations in
 502 plasma as “plasma”, and not as “plasma + ST0” according to the biokinetic Ce model (Leggett et al.
 503 2014). For the uncertainty of model prediction in the blood clearance of Ce, a plasma volume of 3 L
 504 was applied; the solid red line represents the 50th percentile of prediction; the black dashed lines
 505 denote the 2.5th and 97.5th percentiles.

506

507